Abstract
Hemodialysis adequately controls serum uric acid (UA) levels, making UA-lowering drugs unnecessary; scant data are available for peritoneal dialysis (PD). We analyzed blood, 24 h urine and dialysis fluid from twenty patients under PD, to assess UA levels and clearances, and factors associated with better performance and maintenance of target levels (<6mg/dL). Median serum UA was 5.4 mg/dL (p25–75 4.4–5.8), mainly achieved through peritoneal clearance (3.0 mL/min/1.73m2, 71.2% of total UA clearance); 75% of participants was on UA targets. Continuous cycling peritoneal dialysis showed highest UA clearance and target achievements. These findings may be of interest for end-stage renal patients with gout.
Acknowledgements
Ms. Megan Harris performed the English language editing of this manuscript.
Competing interests
MA has received speaking and advisory fees from Menarini, Astra-Zeneca, Grünenthal and Horizon. JPC declares speaking and advisory fees from Baxter, Fresenius Medical Care and Fresenius Kabi. CDL declares no conflicts of interest in the performance of this work.
Contributions
CDL wrote the first draft. All authors contributed to the writing of the manuscript and approved the final version.
Ethics
The study was approved by the Alicante General University Hospital-ISABIAL ethics committee (act 2019/03). Patients granted consent to participate in the study.
Consent for publication
Not applicable.
Availability of data and materials
The data that support the findings of this study are available from the authors upon reasonable request.
Funding
This study had no external funding source.